0.31
Schlusskurs vom Vortag:
$0.269
Offen:
$0.28
24-Stunden-Volumen:
989.02K
Relative Volume:
0.09
Marktkapitalisierung:
$19.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+13.85%
1M Leistung:
-27.92%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Firmenname
Aspire Biopharma Holdings Inc
Sektor
Branche
Telefon
561-704-8527
Adresse
194 CANDELARO DRIVE, #233, HUMACAO
Vergleichen Sie ASBP mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ASBP
Aspire Biopharma Holdings Inc
|
0.31 | 19.75M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
Aspire Biopharma Holdings relocates headquarters to Florida - Investing.com
Aspire Biopharma Relocates Executive Office to Florida - TipRanks
Michael Howe takes helm as CEO of Aspire Biopharma By Investing.com - Investing.com South Africa
Aspire Biopharma Holdings, Inc., Announces Michael C. HoweWith Decades of Experience at Leading and Building Brands in the Healthcare and Consumer SpaceTo Be Its New Chief Executive Officer - El Paso Times
Aspire Biopharma Appoints New Chief Executive Officer - marketscreener.com
Aspire Biopharma CEO Kraig Higginson Steps DownSEC Filing - MarketScreener
Aspire Biopharma Appoints New CEO Michael C. Howe - TipRanks
Michael Howe takes helm as CEO of Aspire Biopharma - Investing.com
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Columbus Dispatch
Aspire Biopharma (NASDAQ:ASBP) Rating Lowered to Strong Sell at Wall Street Zen - Defense World
ASBP Stock Price and Chart — NASDAQ:ASBP - TradingView
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Aspire Biopharma provides development update on BUZZ BOMB supplement - Yahoo Finance
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025 - Akron Beacon Journal
Aspire Biopharma (ASPH) Stock Explodes Over 160%: What's Behind the Monumental Surge? - Daily Chhattisgarh News
Pharma Stock Massively Bid Up Following New Product Announcement - The Globe and Mail
Aspire Biopharma To Launch BUZZ BOMB Sublingual Pre-Workout; Begins Production And Testing - Nasdaq
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
ASBP stock touches 52-week low at $0.22 amid sharp annual decline - Investing.com India
Sidoti Events, LLC's Virtual May Micro-Cap Conference - FinancialContent
Vita Bella Partners with New to The Street for National Media Campaign - Lohud
Aspire Biopharma announces resale of up to 11.26M shares - MSN
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21 - ACCESS Newswire
ASBPAspire Biopharma Holdings Inc Latest Stock News & Market Updates - Stock Titan
Aspire Biopharma Holdings Inc (ASBP) Stock: A Comprehensive 52-Week Review - investchronicle.com
Was anything negative for Aspire Biopharma Holdings Inc (ASBP) stock last session? - uspostnews.com
Post-Trade Analysis: Aspire Biopharma Holdings Inc (ASBP) Slides -15.33, Closing at 0.36 - DWinneX
Aspire Biopharma Settles with Lenders, Extends Loan Maturities By Investing.com - Investing.com Nigeria
Aspire Biopharma Settles with Lenders, Extends Loan Maturities - Investing.com Australia
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Joplin Globe
Press Release Distribution & PR Platform - ACCESS Newswire
Former Nasdaq Private Market President Takes LogicMark's Helm: Inside the AI-Driven Healthcare Tech Transformation - Stock Titan
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17 - ACCESS Newswire
Finanzdaten der Aspire Biopharma Holdings Inc-Aktie (ASBP)
Es liegen keine Finanzdaten für Aspire Biopharma Holdings Inc (ASBP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):